Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
AUSCANN GROUP HOLDINGS LTD |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.0400 AUD | -4.76% | -.--% | -.--% | |
| Dec. 01 | Auscann Group Appoints Nonexecutive Chair | MT |
| Aug. 31 | AusCann Group Holdings Ltd Reports Earnings Results for the Full Year Ended June 30, 2023 | CI |
| Sales 2023 | 1.55 M 1.03 M | Sales 2024 * | - | Capitalization | 17.62 M 11.76 M |
|---|---|---|---|---|---|
| Net income 2023 | -10.00 M -6.67 M | Net income 2024 * | - | EV / Sales 2023 | 6,66x |
| Net cash position 2023 | 7.30 M 4.87 M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 | -1,61x | P/E ratio 2024 * | Employees | - | |
| Yield 2023 | - | Yield 2024 * |
-
| Free-Float | 85.68% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.76% |
3 years
0.04
0.30
5 years
0.040.79
10 years
0.041.86
| Managers | Title | Age | Since |
|---|---|---|---|
Christopher Mews
DFI | Director of Finance/CFO | - | 2019 |
Susan Park
SEC | Corporate Secretary | 48 | 2016 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tod McGrouther
CHM | Chairman | - | 2021 |
Christopher Mews
DFI | Director of Finance/CFO | - | 2019 |
Robert Clifford
BRD | Director/Board Member | - | 2021 |
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Its products include Neuvis, CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways. MicroMAX is an encapsulation technology for use in the field of animal therapeutics. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.
Sector
Pharmaceuticals
Calendar
2024-02-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 12 M $ | |
| +59.64% | 525 B $ | |
| -10.34% | 381 B $ | |
| -6.75% | 262 B $ | |
| -11.26% | 253 B $ | |
| -17.52% | 221 B $ | |
| +2.14% | 202 B $ | |
| -9.09% | 200 B $ | |
| -43.58% | 163 B $ | |
| +3.74% | 146 B $ |
